Postexposure prophylaxis for human immunodeficiency virus infection after sexual or injection drug use exposure: Identification and characterization of the source of exposure

Journal of Infectious Diseases

Volumn 184, Issue 12, 2001, Pages 1608-1612

  Roland, Michelle E ^a   Martin, Jeffrey N ^a,b   Grant, Robert M ^a,c   Hellmann, Nicholas S ^e   Bamberger, Joshua D ^d   Katz, Mitchell H ^a,d   Chesney, Margaret ^b   Franses, Karena ^b   Coates, Thomas J ^b   Kahn, James O ^a  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Department of Public Health ^*  (United States)

^e MONOGRAM BIOSCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ILLICIT DRUG; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; NUCLEOSIDE ANALOG; VIRUS RNA;

ADULT; ANAMNESIS; ANTIBIOTIC THERAPY; ARTICLE; BLOOD LEVEL; DRUG USE; EVALUATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PREDICTION; PRIORITY JOURNAL; SEXUAL BEHAVIOR;

ADULT; ANTI-HIV AGENTS; CONTACT TRACING; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; RNA, VIRAL; SEXUAL BEHAVIOR; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 0035892805     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/324580     Document Type: Article

References (13)

1. Updated US Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis
2. Management of possible sexual, injecting-drug-use, or other nonoccupational exposure to HIV, including considerations related to antiretroviral therapy. Public Health Service statement
3. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: The San Francisco PEP Study
4. Survey of nonoccupational HIV postexposure prophylaxis in hospital emergency departments
5. Nonoccupational HIV post exposure prophylaxis (PEP) in Australia
6. A retrospective study of 83 postexposure prophylaxis (PEP) tolerability in health dispensary Figuier, DASES, Paris, France
7. Offering HIV prophylaxis to people who have been sexually assaulted: 16 months' experience in a sexual assault service
8. Tolerability of postexposure prophylaxis with zidovudine, lamivudine, and nelfinavir for human immunodeficiency virus infection
9. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
10. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1
11. Cost-effectiveness of post-exposure prophylaxis following sexual exposure to HIV
12. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed
13. Post-exposure prophylaxis (PEP) for sexual exposure to HIV does not lead to increases in high risk behavior: The San Francisco PEP Project